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Accelerated long-term forgetting in healthy
older adults predicts cognitive decline over
1 year
Alfie R. Wearn1,2* , Esther Saunders-Jennings1, Volkan Nurdal1,3, Emma Hadley1, Michael J. Knight4,
Margaret Newson2,4, Risto A. Kauppinen3 and Elizabeth J. Coulthard1,2
Abstract
Background: Here, we address a pivotal factor in Alzheimer’s prevention—identifying those at risk early, when
dementia can still be avoided. Recent research highlights an accelerated forgetting phenotype as a risk factor for
Alzheimer’s disease. We hypothesized that delayed recall over 4 weeks would predict cognitive decline over 1 year
better than 30-min delayed recall, the current gold standard for detecting episodic memory problems which could
be an early clinical manifestation of incipient Alzheimer’s disease. We also expected hippocampal subfield volumes
to improve predictive accuracy.
Methods: Forty-six cognitively healthy older people (mean age 70.7 ± 7.97, 21/46 female), recruited from databases
such as Join Dementia Research, or a local database of volunteers, performed 3 memory tasks on which delayed
recall was tested after 30 min and 4 weeks, as well as Addenbrooke’s Cognitive Examination III (ACE-III) and CANTAB
Paired Associates Learning. Medial temporal lobe subregion volumes were automatically measured using high-
resolution 3T MRI. The ACE-III was repeated after 12 months to assess the change in cognitive ability. We used
univariate linear regressions and ROC curves to assess the ability of tests of delayed recall to predict cognitive
decline on ACE-III over the 12 months.
Results: Fifteen of the 46 participants declined over the year (≥ 3 points lost on ACE-III). Four-week verbal memory
predicted cognitive decline in healthy older people better than clinical gold standard memory tests and
hippocampal MRI. The best single-test predictor of cognitive decline was the 4-week delayed recall on the world
list (R2 = .123, p = .018, β = .418). Combined with hippocampal subfield volumetry, 4-week verbal recall identifies
those at risk of cognitive decline with 93% sensitivity and 86% specificity (AUC = .918, p < .0001).
Conclusions: We show that a test of accelerated long-term forgetting over 4 weeks can predict cognitive decline
in healthy older people where traditional tests of delayed recall cannot. Accelerated long-term forgetting is a
sensitive, easy-to-test predictor of cognitive decline in healthy older people. Used alone or with hippocampal MRI,
accelerated forgetting probes functionally relevant Alzheimer’s-related change. Accelerated forgetting will identify
early-stage impairment, helping to target more invasive and expensive molecular biomarker testing.
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Background
Identifying and treating neuropathology leading to Alz-
heimer’s disease (AD) dementia in the early stages, when
symptoms are minimal, is the optimal strategy to main-
tain quality of life. Developing effective treatments for
AD may have been hampered by a failure to detect dis-
ease before pathological decline becomes inexorable [1].
Predicting progression at the stage of mild cognitive im-
pairment (MCI) has had some success [2, 3]. However,
in order to identify patients early, we need a marker that
can be easily applied at scale with low cost and low pa-
tient burden at a stage before patients have symptoms
that impair quality of life. If successful in trials, such a
marker could be integrated into clinical care to enable
early diagnosis and treatment.
Long-term memory over days or weeks may be an ef-
fective early marker of AD. Delayed recall over 1 week
on a story task has been shown to have a much greater
ability to distinguish healthy controls from those with
MCI than recall over 30 min [4]. Another study showed
that a delay of 6 weeks on story and complex figure re-
call tasks could identify significant impairment in a
group of people who report ‘subjective’ memory impair-
ment but who have no objective memory deficit on
standard cognitive tests including delayed recall after 30
min [5]. This highlights that people with ‘subjective’
memory impairment may, in some cases, simply have
impairment for which standard tests lack sufficient sen-
sitivity. In a presymptomatic autosomal dominant AD
cohort, Weston et al. [6] demonstrate that long-term
memory on a verbal recall test over a 1-week delay not
only highlights significant impairment but also predicts
years-to-expected-age-of-dementia-onset. Finally, 1-week
verbal memory is also impaired in otherwise asymptom-
atic APOE ε4 homozygotes compared to people with
one or no ε4 alleles [7].
These longer-term memory tests may tax memory cir-
cuit functionality more than 30-min delayed recall
tests—the current clinical gold standard cognitive task
for detecting episodic memory problems which could be
an early clinical manifestation of incipient AD. This ‘ac-
celerated long-term forgetting’ (ALF) phenotype may
represent a failure of memory consolidation processes
[8] whereby information can be retained for short pe-
riods of time, but a successful conversion of labile short-
term memory traces to permanent long-term memory is
impossible. Such processes are thought to be primarily
governed by the medial temporal lobe (MTL) [9–12],
within which ALF may enable earlier identification of
dysfunction.
The memory impairment observed in the earliest signs
of AD can be attributed to damage to the hippocampus
and MTL cortices. MTL atrophy, measured using mag-
netic resonance imaging (MRI), is a non-invasive early
marker often in routine clinical use [13]. MTL areas af-
fected early in AD are often reduced in volume even
prior to the onset of clinically detectable cognitive symp-
toms [14].
In the present study, we aimed to test whether delayed
recall over 4 weeks is a more sensitive early marker of
AD-related cognitive decline than traditional tests of
memory over 30 min. We also explored whether MTL
subfield volume could complement ALF in identifying
early signs of AD.
Methods
Participants
We recruited 53 cognitively healthy community-dwelling
older participants with Addenbrooke’s Cognitive Exam-
ination III (ACE-III) scores of > 88, the upper threshold
for detecting mild cognitive impairment [15]. Forty-six
returned for follow-up 1 year later (mean age 70.7 ±
7.97). Twenty-one (46%) of these participants were fe-
male, and participants had 16.2 ± 3.52 years of education.
Participants were recruited from local volunteer data-
bases, the Join Dementia Research platform and word of
mouth. All participants were verbally screened for a his-
tory of neurological disorders and memory problems in
a telephone interview. All patients provided informed
written consent prior to testing. Ethical approval was
given by Frenchay NHS Research Ethics Committee.
Cognitive testing
Cognitive change over the year was assessed using the
Addenbrooke’s Cognitive Examination III (ΔACE-III), a
freely available 15-min routine test for global cognition
with high reliability and utility in dementia diagnosis
[15–17]. The ACE-III comprises tests for 5 cognitive do-
mains: attention, memory, language, fluency and visuo-
spatial, and is scored out of a maximum of 100. Multiple
versions of the ACE-III are available to allow for retest-
ing. The version assigned to each participant at their
baseline visit (either A or B) was randomized. The
remaining version was administered at follow-up.
Delayed recall over 30 min and 4 weeks was tested on
three separate tests:
1) Word list—a 16-word list based on the California
Verbal Learning Task-II (CVLT-II) [18]; maximum
score, 16
2) Story—from the Rivermead Behavioural Memory
Test-3 (RBMT-3) [19]; maximum score, 21
3) Complex figure—based on the Rey-Osterrieth Com-
plex Figure Task (RCFT) [20]; maximum score, 36
These tests were adapted from their standard proto-
cols (i.e. that of CVLT-II, RBMT-3 or RCFT) in that par-
ticipants were trained to 75% accuracy on each test, with
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2–5 learning trials to equate learning between individ-
uals [21]. Standard CVLT-II procedure involves exactly
5 learning trials, and standard RBMT-3 story protocol
involves just one, regardless of performance. Similarly,
the RCFT procedure usually incorporates just one copy
and one recall test during the learning phase. For the
adapted complex figure task, copy and recall trials were
both repeated 2–5 times throughout the learning phase.
Both delayed recall time points were performed in per-
son, and participants were not told that recall would be
tested after 4 weeks.
We took a pragmatic approach in this paper to try and
identify the ideal test which would be quick and easy to
administer and provide high sensitivity and specificity.
Although a single test would be ideal, as it would be
feasible to do all 3 of these tests in clinical practice we
calculated the composite score (by averaging the scores
as a proportion of the maximum possible score for each
test) to see if we could increase the sensitivity and speci-
ficity at any given testing time point for cognitive decline
over a year. A priori (based on data generated by others),
we suspected that either word list memory or story
memory over 4 weeks would be most sensitive to AD-
related cognitive change.
Further testing included the Paired Associate Learning
(PAL) using CANTABeclipse v5 (Cambridge Cognition
Ltd.; Cambridge, UK). This test has demonstrated utility
in detecting cognitive deficit due to AD [22–25], so we
included it to compare whether our tests could better
predict cognitive decline. However, we acknowledge this
test is not without its criticisms and limitations [26, 27].
Measures used included total accuracy, mean reaction
time and maximum level reached.
Imaging parameters
All MRI scans were acquired on a Siemens Magnetom
Skyra 3T system. The volumetric imaging protocol in-
cluded a 3D T1-weighted MPRAGE (acquired resolution
0.86 mm isotropic) and two 2D T2-weighted high-
resolution hippocampal turbo spin-echo sequences
(multi-contrast and single-contrast) (reconstructed reso-
lution 0.34 × 0.34 × 1.5 mm). Full imaging details are as
described by Nurdal et al. [28].
Image analysis
MTL subfields were demarcated using the automated
hippocampal subfield segmentation (ASHS) software
(rev103), using the UPENN atlas comprising a mixture
of older adults and MCI patients [29]. An example of
ASHS output is shown in Fig. 1. All hippocampal masks
created as an output of ASHS were visually inspected for
quality. In cases where the multi-echo image was either
not present or of too poor quality due to movement ar-
tefacts, the single-echo TSE was used instead. We have
shown in-house that ASHS outputs from either scan
type are not significantly different from one another.
Three participants were excluded from the volumetric
analysis due to poor mask quality. Analysis of individual
subfields was performed on CA1, dentate gyrus (DG),
subiculum (SUB), entorhinal cortex (EC) and perirhinal
cortex (PC). PC was defined as the BA35 label in the
UPENN atlas. CA2 and CA3 were included in models
combining all subfields. Whole hippocampal volume
(CA1–3 + DG + SUB) was also analysed, to highlight the
added value of subfield analyses. Volumes were all nor-
malized to intracranial volume.
Statistical analyses
Main analyses
Predictive power of delayed recall scores was performed
in two ways: continuous and discrete (‘did they decline
or not?’). For the former ‘continuous’ analysis, univariate
linear regressions with delayed recall score of a given
test as the independent variable and ΔACE-III as the
outcome variable. For the latter ‘discrete’ analysis, partic-
ipants were split into two groups: those whose ACE-III
scores declined over the year vs those whose scores did
not decline.
This threshold was defined by the reliable change
index (RCI) [30], which is calculated using the following
formulae:
SE ¼ SDnorm 
ffiffiffi
2
p

ffiffiffiffiffiffiffiffiffi
1 − r
p
RCI ¼ SE 1:96
where SE is the standard error of change on a test,
SDnorm is the standard deviation of ACE-III score in the
normative data (2.7) [15] and r is the reliability of the
test, in this case, given as Cronbach’s alpha (0.88) [16].
The resulting reliable change index is 2.59. Therefore, a
Fig. 1 MTL subfield mask example. Three skull-stripped coronal
sections of summed-over-echoes T2-w scan of a single participant
are shown with anterior MTL (head) on the left and posterior
hippocampus (tail) on the right. Shown are subfields CA1 (red), CA2
(light green), CA3 (yellow), DG (light blue), EC (dark green), BA35
(dark blue) and BA36 (grey)
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decline of 3 or more points was deemed representative
of mild but statistically significant cognitive decline.
We used receiver operating characteristic (ROC)
curves to assess the predictive capability of each variable
in identifying those who declined vs those who did not.
Predicted probabilities from multiple logistic regressions
were used to create ROC curves of multiple combined
variables. ROC Curves were assessed using the area
under the curve (AUC) and compared using DeLong’s
test for dependent ROC curve comparisons [31]. Stand-
ard errors (SE) for AUC are shown in the supplementary
information (Supplementary Table 2).
Exploratory analysis
In order to fully assess the added value of MRI volume-
try in predicting cognitive decline, we calculated ROC
AUC for various combinations of variables (Supplemen-
tary Table 2). In order to explore the relationships be-
tween different tests of delayed recall, we also calculated
Pearson’s correlation coefficients for each pairing (sup-
plementary Table 1).
All reported p values are two-tailed (α = 0.05), and un-
corrected for multiple comparisons given that tests were
not fully independent from one another (supplementary
Table 1). However, Bonferroni-corrected p values (cor-
rected across all 3 delayed recall tests) are shown where
appropriate for full transparency (as pbonferroni). All ana-
lyses were performed in IBM SPSS Statistics 24, except
DeLong tests to compare ROC curves which were car-
ried out in MedCalc v19.4.
Results
Four-week (4w) recall on the word list task predicted
ΔACE-III (R2 = .123, p = .018; pbonferroni = .054) (Table 1;
Fig. 2). There was no such relationship between ΔACE-
III and 30-min (30m) recall on the word list (R2 = .028,
p = .274; pbonferroni = .822). Scores at either time point of
the story (30m: R2 = .006, p = .629; 4w R2 = .027, p = .289)
and complex figure tasks (30m: R2 = .0003, p = .912; 4w:
R2 = .045, p = .171) could not predict ΔACE-III. Strik-
ingly, in this healthy cohort, neither whole hippocampal
volume nor volume of any single hippocampal subfield
or MTL cortical region was correlated with change in
performance over the year (Table 1). Furthermore, PAL
measures did not predict cognitive decline.
The 4w composite score significantly positively pre-
dicted ΔACE-III (R2 = .152, p = .013, β = .390), yet 30m
composite recall score did not (R2 = .021, p = .378, β =
.143) (Fig. 2).
Fifteen of the 46 people in this cohort declined more
than expected using the reliable change index. Demo-
graphic and delayed recall data for decliners and non-
decliners are shown in Table 2. Raw cognitive test data
for each can be found in supplementary information.
Both 30m and 4w word list recall scores distinguished
decliners from non-decliners. In line with our hypoth-
esis, the 4w recall time point had the strongest discrim-
inatory power for a single variable with an AUC of .752
(SE = .078, p = .007). 30m verbal recall (AUC = .687, SE =
.080 p = .047), and 30m (story: AUC = .699, SE = .083,
p = .040; complex figure: AUC = .497, SE = .099, p = .979)
and 4w measures (story: AUC = .671, SE = .083, p = .079;
complex figure: AUC = .625, SE = .090, p = .191) in other
tests had weaker discriminatory power. The 4w compos-
ite recall score was able to predict ACE-III decline status
(AUC = .761, SE = .076, p = .008), whereas the 30m com-
posite score was less effective (AUC = .674, SE = .085,
p = .078). Comparing the ROC curves using the Delong
method [31] did not reveal statistically significant differ-
ences between 30m and 4w AUCs for any test (word list:
p = .472; story: p = .785; complex figure: p = .437; com-
posite: p = .369).
Combining memory test scores with MTL regional
volumes improves classification. 4w word list recall com-
bined with individual subfield volumes produced the
best single-test model with an AUC of .918 (p < .0001;
Fig. 3). The optimal cut-off has 93% sensitivity and 86%
specificity. The equivalent model using 30m word list re-
call score achieved an AUC of .829 (p = .001). In com-
parison, MTL subfields alone produced a predictive
Table 1 Univariate linear regression statistics for delayed recall,
PAL scores and MTL region volumes predicting ΔACE-III
Predictors β (standardized) R2 p Number
Word List
30m .167 .028 .274 45
4w .350 .123 .018 45
Story
30m .076 .006 .629 43
4w .165 .027 .289 43
Complex figure
30m .018 .0003 .912 42
4w .246 .061 .116 42
PAL
Accuracy .194 .037 .225 41
Reaction time − .021 .0004 .898 41
Max level .064 .004 .689 41
Whole hippocampus − .072 .005 .646 43
CA1 − .084 .007 .590 43
DG − .059 .003 .707 43
SUB .005 < .0001 .976 43
EC .098 .010 .532 43
PC .173 .030 .269 43
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model with an AUC of .802 (p = .001). All ROC data can
be seen in supplementary Table 2.
Discussion
We report that extending the delay period over which
recall, particularly verbal recall, is tested from 30min to
4 weeks can markedly improve the identification of
people likely to decline cognitively in the coming year.
This is the first time this has been shown in a longitu-
dinal cohort study. ALF improves classification accuracy
beyond that which is achieved using MTL subfield vol-
umes. These findings support the clinical utility of much
longer-term memory tests in identifying the very subtle
neuropathology that occurs years before a diagnosis of
AD dementia [32], though further research is required
to fully validate their use in predicting conversion to
dementia.
Previous work in a selective presymptomatic cohort
with the extremely rare autosomal dominant form of
Alzheimer’s disease suggested that ALF might be a
Fig. 2 Delayed recall predicting cognitive decline over 1 year: linear regressions (left) and ROC curves (right). Linear regression panels (left) show
raw data for each test and ΔACE-III. Smaller scores on a 4-week word list recall indicate a more negative score change. Solid lines represent
statistically significant regressions/ROC curves (p < .05). Dotted lines represent non-significant regressions/ROC curves (p > .05). 30m, 30-min recall
scores; 4w, 4-week recall scores; ACE-III, Addenbrooke’s Cognitive Examination III
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sensitive marker of early change despite having normal
scores after a 30-min delay [6]. They tested all three of a
story, word list and complex figure task over a delay of
1 week, and only on the word list was longer-term mem-
ory worse in genetically at-risk participants. Here, we
utilized a real-world sample to reveal that long-term
word list memory has the potential to be applied to the
general older population as a marker of future cognitive
decline. These complementary findings suggest that the
word list may present the best single test to predict at-
risk patient groups and that story learning or visuo-
spatial memory tasks may be less sensitive. Alignment of
our results with those from a different study in a cohort
genetically at-risk is encouraging as to the reliability of
this finding. Future clinical trials could utilize memory
tests over a longer time frame as a sensitive marker of
change. It should be noted that the 4-week verbal recall
test predicting cognitive change over the year was not
below the α threshold of statistical significance after a
Bonferroni correction (p = .054) across the 3 cognitive
tests used. However, the Bonferroni method is a highly
conservative method of correcting for multiple compari-
sons, and given that the three tests cannot be regarded
as fully independent (as shown in supplementary
Table 1), we believe this still to be a robust, albeit pre-
liminary, finding. Future work should aim to confirm or
deny this finding.
ROC curves for word list recall show that very high
levels of sensitivity are achievable with small trade-offs
in specificity. For example, a cut-off score of 4.5 at the
4w time point allows 93% of people who decline by
more than three points on ACE-III to be detected, even
though 55% of people below this cut-off do not decline
by more than this amount. This enables the test to be
used as a wide-net screening tool, the main goal of
which is to reduce the number of people having more
expensive and invasive testing for probable AD, such as
CSF analyses or amyloid/tau PET scans [33]. A 4-week
memory task takes only a few minutes to administer and
could transform standard clinical neuropsychology test-
ing (where delayed recall of a word list over 30 min is
usually administered). This test could even be adapted
to be performed over the phone or delivered by a mobile
app, to reduce face-to-face clinic visits. There is the cav-
eat of having to wait 4 weeks to get any result from this
test. However, although we used a 4-week delay para-
digm in this study, we do not show that it is necessary
to wait this long to measure ALF. Indeed, shorter delays
are less susceptible to confounding from the variation in
events between delay time points. The delay period in
past work ranges from 1 to 6 weeks [4–6], but further
work is required to determine the optimal delay that is
sensitive to cognitive dysfunction, but least burdensome
for participants and clinicians.
Given the critical role for MTL in long-term memory
consolidation [34], ALF may reflect subtle MTL damage,
such as that which occurs in the prodromal stages of
AD. In combination with MTL subregion volumes, 4-
week verbal recall scores predict cognitive decline in
cognitively healthy individuals with sensitivity and speci-
ficity similar to that of much more expensive molecular
biomarkers tests (PET scanning and CSF analysis) [35–
Table 2 Demographic information and delayed recall data for
people who did or did not decline over the year
Non-decliner Decliner Total
N (male:female) 31 (16:15) 15 (9:6) 46 (25:21)
Age (years) 71.1 ± 8.92 69.9 ± 5.74 70.7 ± 7.97
YOE 16.7 ± 3.41 15.1 ± 3.61 16.2 ± 3.35
ACE-III /100
Baseline 95.0 ± 3.03 94.7 ± 3.20 94.9 ± 3.05
Follow-up 96.1 ± 2.73 90.5 ± 3.14 94.2 ± 3.88
Word list /16
30m 11.5 ± 2.55 9.73 ± 2.37 10.9 ± 2.61
4w 4.35 ± 2.79 2.14 ± 2.03 3.67 ± 2.76
Story /21
30m 16.0 ± 2.22 14.2 ± 2.49 15.4 ± 2.42
4w 9.70 ± 4.07 7.65 ± 2.85 9.08 ± 3.83
Complex figure /36
30m 31.0 ± 2.57 30.2 ± 4.07 30.7 ± 3.15
4w 13.5 ± 6.42 11.5 ± 4.95 12.9 ± 5.99
Data are shown as mean ± standard deviation. Maximum scores for each
cognitive test are shown in the left column
YOE years of education, 30m 30-min delayed recall time point, 4w 4-week
delayed recall time point
Fig. 3 Accuracy of delayed verbal recall and MTL subfield volumes
predicting cognitive decline. Shown are receiver operating characteristic
(ROC) curves for individual combined subfields (CA1–3, DG, EC, BA35)
and either 30-min (30m) or 4-week (4w) recall on the word list
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37]. The present analyses provide further justification for
the incorporation of MRI and automated volumetry
techniques in clinical diagnostic processes [13, 38, 39].
As neuroimaging, often MRI, is part of routine clinical
screening processes for neurological disease, the com-
bination of cognitive tests with volumetry is highly prac-
tical and easily translatable. It is interesting to note that
although MTL volumes are able to predict the presence
or absence of cognitive decline (in our ROC analysis),
they were very poor in predicting any linear association
with cognitive change. This may indicate a non-linear
relationship between the two, whereby only MTL values
below a certain threshold are indicative of cognitive de-
cline, and cognitive change in people with larger MTL
volumes is more determined by other factors (such as
tissue damage that has not yet resulted in volume
change detectable on MRI [40, 41]). This supports theor-
ies of graceful degradation and cognitive reserve [42]
and should be further explored in studies with larger
sample sizes. ALF may also require the functionality of
networks beyond the MTL that are still affected in early
AD, such as those involving the thalamus [43].
It could be suggested that the observed ALF pheno-
type is explained by the differences in practice effects be-
tween individuals. Lack of practice effects (failure to
improve performance when a task is repeated) has been
shown to be predictive of cognitive decline in people
with amnestic mild cognitive impairment [44]. This
seems relatively unlikely to be the case here as task in-
structions requirements were conceptually very simple—
free recall tests, rather than re-administration of any
learning materials. Furthermore, during the learning
phase, differences in individual learning rates were con-
trolled for by including the 75% accuracy threshold,
above which learning stimuli were not repeated. We
therefore believe an attenuated practice effect to be a
distinct measure, albeit potentially with similar neuro-
biological underpinnings, whereby impaired memory
consolidation circuits may impair an individual’s ability
to benefit from repeated trials.
Limitations
A limitation of the present study is that the global cogni-
tive decline seen over the year cannot be directly attrib-
uted to AD without assessment of amyloid and/or tau
status via CSF or PET. This was not collected as part of
the present study but is an area of future interest and
presents an obvious next step for this research. Despite
this, we suggest that tests of delayed recall may predict
cognitive decline that is specifically due to AD pathology
given the role of MTL in long-term memory consolida-
tion [34, 45] and the susceptibility of MTL to early AD
pathology. Furthermore, as discussed, this study is highly
in line with the findings of Weston et al. [6], which dir-
ectly links delayed recall over days/weeks to autosomal
dominant AD.
Although the 4-week recall time point of the word list
task produced the greatest AUC for any single cognitive
test in detecting which people experienced cognitive de-
cline, the differences between time points were relatively
small. This is in part due to the high correlations be-
tween test time points, at least for the story and word
list (supplementary Table 1); however, this is also due to
our relatively small sample size. A larger sample size
would be required to confirm that differences in classifi-
cation ability are statistically significant, as well as to im-
prove the certainty of conclusions from all conducted
analyses. Future studies may use our findings to assist in
calculating sample sizes required for sufficient power to
detect such statistical differences.
Throughout this paper, we discuss mild cognitive de-
cline defined as a statistically reliable change in score on
the ACE-III, a test of general cognitive function. Al-
though a drop of just 3 points is statistically significant,
it may not be clinically significant in terms of a func-
tional decline and is certainly not necessarily indicative
of a decline to a level of MCI. Given the group (healthy
older adults), sample size (46) and follow-up period of
this study (1 year), a subtle measure of cognitive change
was necessary, as opposed to measuring conversion to
MCI or AD. We infer that a subtle cognitive decline
over this timescale may indicate further cognitive decline
over longer timescales. In this regard, the marker does
not necessarily need to be directly clinically functionally
significant, but rather, it would herald the need for fur-
ther investigation to detect the cause of the change and,
where possible, avoid a functionally significant change.
Further follow-ups of these participants would be neces-
sary to observe which people decline further or even
which people later receive diagnoses of dementia. Fur-
ther research is also required to explicitly test the re-
sponsiveness of the ACE-III to detecting subtle cognitive
decline.
Another limitation of our study is the validity of
the cognitive tests used to measure delayed recall. Al-
though based on well-validated tasks designed to
measure recall at 30 min, we modified the protocols
slightly (e.g. by including a learning criterion and
varying the number of learning trials). In doing so,
there was a risk that we invalidated the tests for
measuring delayed recall at 30 min. Although the data
are not comparable to normative data of the tests on
which they are based, we believe they still provide ro-
bust measures of delayed recall at both time points as
we observed substantial variation in scores at both
time points in all 3 tests, indicating a lack of floor
and ceiling effects.
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Finally, it could be argued that an incorporation bias
exists, given that the cohort was defined as healthy by
having an ACE-III > 88, 26 points of which are achieved
from tests of memory. We do not believe this to be a
factor which biases our results, as memory is tested over
delays of no more than 10 min during the ACE-III, and
this forms a small part of the entire ACE-III score (the
10-min delayed recall test is worth just 7 points in total).
Even if the cohort was defined solely on having normal
30-min recall at baseline, this could not be expected to
influence whether 30-min or 4-week memory would bet-
ter predict cognitive decline over the year.
Conclusions
In summary, we show that a test of accelerated long-
term forgetting over 4 weeks can predict cognitive de-
cline in healthy older people where traditional tests of
delayed recall cannot. This highlights its potential in
screening patients for clinical trials and practice either in
conjunction with volumetry or as a standalone test. This
could reduce the number of patients who need
expensive biomarker testing for Alzheimer’s disease, in-
creasing the feasibility of large-scale early clinical trials.
Further research is required to explore the relationship
between ALF and molecular biomarker profiles to define
the specificity of longer-term recall deficits to early AD
pathology.
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